Want to see JP:4671 full AI Analyst Report?

FALCO HOLDINGS Co., Ltd (4671) Price & Analysis

1 Followers

4671 Stock Chart & Stats

¥2681.00

-¥4.00(-0.17%)

At close: Jan 08 4:00 PM EST

¥2681.00

-¥4.00(-0.17%)

Day’s Range― - ―

52-Week Range¥2,290.00 - ¥2,775.00

Previous CloseN/A

Volume5.90K

Average Volume (3M)15.38K

Market Cap

¥26.54B

Enterprise Value¥18.37K

Total Cash (Recent Filing)¥9.27B

Total Debt (Recent Filing)¥1.25B

Price to Earnings (P/E)13.4

Beta0.54

Next Earnings

Aug 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield4.63%

Share Statistics

EPS (TTM)201.19

Shares Outstanding10,680,177

10 Day Avg. Volume10,950

30 Day Avg. Volume15,383

Financial Highlights & Ratios

PEG Ratio1.23

Price to Book (P/B)1.01

Price to Sales (P/S)0.60

P/FCF Ratio17.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)182.7

Revenue Forecast (FY)¥43.60B

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthVery low and improving leverage provides durable financial flexibility. With minimal debt burden the company can fund operations, capex, dividends or opportunistic M&A without heavy refinancing risk, increasing resilience through cyclical healthcare demand shifts.

Consistent Cash GenerationSustained positive operating and free cash flow support self-funding of working capital, capex and shareholder returns. Persistent cash generation underpins long-term financial plans and reduces reliance on external financing despite some year-to-year volatility.

Stable, Contracted Revenue BaseCore clinical testing services and longstanding contracts with hospitals and pharma create recurring, defensive revenue. As an essential diagnostics provider the company benefits from structural healthcare demand and sticky customer relationships over multi-year horizons.

Bears Say

Uneven Revenue GrowthRevenue recovery has been uneven following prior declines, indicating limited momentum and potential dependence on cyclical or one-off drivers. Persistent modest top-line growth constrains scale advantages and makes long-term earnings expansion more uncertain.

Compressed ProfitabilityOperating and net margins have trended lower from peak levels, reducing earnings power. Sustained margin compression limits the firm's ability to reinvest, boost returns on equity, and maintain generous distributions without operational improvements or pricing leverage.

Volatile Cash ConversionWhile FCF is positive, conversion at roughly half of net income and historical swings increase uncertainty around available discretionary cash. This volatility can constrain consistent capital allocation, make planning harder, and raise dependence on balance-sheet liquidity.

4671 FAQ

What was FALCO HOLDINGS Co., Ltd’s price range in the past 12 months?

FALCO HOLDINGS Co., Ltd lowest stock price was ¥2290.00 and its highest was ¥2775.00 in the past 12 months.

What is FALCO HOLDINGS Co., Ltd’s market cap?

FALCO HOLDINGS Co., Ltd’s market cap is ¥26.54B.

When is FALCO HOLDINGS Co., Ltd’s upcoming earnings report date?

FALCO HOLDINGS Co., Ltd’s upcoming earnings report date is Aug 05, 2026 which is in 15 days.

How were FALCO HOLDINGS Co., Ltd’s earnings last quarter?

FALCO HOLDINGS Co., Ltd released its earnings results on May 12, 2026. The company reported ¥60.59 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is FALCO HOLDINGS Co., Ltd overvalued?

According to Wall Street analysts FALCO HOLDINGS Co., Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FALCO HOLDINGS Co., Ltd pay dividends?

FALCO HOLDINGS Co., Ltd pays a Semiannually dividend of ¥64 which represents an annual dividend yield of 4.63%. See more information on FALCO HOLDINGS Co., Ltd dividends here

What is FALCO HOLDINGS Co., Ltd’s EPS estimate?

FALCO HOLDINGS Co., Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FALCO HOLDINGS Co., Ltd have?

FALCO HOLDINGS Co., Ltd has 10,680,177 shares outstanding.

What happened to FALCO HOLDINGS Co., Ltd’s price movement after its last earnings report?

FALCO HOLDINGS Co., Ltd reported an EPS of ¥60.59 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.556%.

Which hedge fund is a major shareholder of FALCO HOLDINGS Co., Ltd?

Currently, no hedge funds are holding shares in JP:4671

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FALCO HOLDINGS Co., Ltd

FALCO HOLDINGS Co., Ltd., a medical services enterprise established in 1962 and headquartered in Kyoto, Japan, primarily delivers clinical diagnostic testing and pharmaceutical dispensing solutions. The company serves medical institutions and various corporations throughout Japan. Its comprehensive range of clinical testing encompasses specialized areas such as genetics, biochemistry, hematology, pathology, immunology, microbiology, and radioimmunoassay. Beyond direct diagnostics, FALCO HOLDINGS also engages in genomic-based drug discovery and the development of biotechnological pharmaceuticals. The company's offerings extend to medical information technology services, as well as environmental and food sanitation testing. They also provide genetic testing tailored for the food industry, catering to manufacturers, retailers, and restaurants. Additionally, FALCO HOLDINGS operates dispensing pharmacies and drugstores. They are also active in the development and sale of medical information systems, notably including "@home Dr.," an electronic medical record system designed for clinics with a high volume of clinical testing, and "TASCAL for ASP," a robust medical support system.